Bio-medical firm expands pioneering technology and launches its Business Expansion Scheme 09 offering
following Enterprise Ireland investment.
EnBIO™, headquartered at Fota Point Business Park, Cork, recently copper fastened its reputation as a
world-leader in pioneering technology in the bio-medical space with the announcement of the launch of a
further new product OsteoZap™.
The company is also launching its Business Expansion Scheme ’09 offering designed to give investors an
opportunity to invest in its portfolio of innovative products which are attracting world acclaim.
Furthermore, following a recent further investment in EnBIO by Enterprise Ireland under the High
Potential Start Up scheme (the third investment in two years) the company, with its experienced team,
aims to achieve significant growth in the short term and has increased its workforce by one third in the
Dan Philpott, CEO of EnBIO said: ‘Our core product, CoBlast™ which was launched last year, is already
being embraced and validated by several blue-chip companies in the medical devices industry and some
non-medical sectors worldwide. Our collaboration with University College Cork, University College Dublin,
the University of Ulster and the University of Liverpool has seen CoBlast™ brought to market successfully.
The new product we are now launching, OsteoZap™, is designed to prevent infection and bio film
formation on orthopaedic implants such as hips and knees, trauma devices, and spinal and dental implants
combines long-term infection prevention with the bone integration benefits of the company’s existing
OsteoZip™ surface which was launched last year. Several international orthopaedic and dental implant
manufacturing companies are interested in the technology and are currently conducting their own
evaluation of the technology and its potential application for their implant product offering.’
EnBIO is collaborating with Clemson University in Greenville, South Carolina (which, according to Dan
Philpott is ‘the ‘Harvard’ of Bio-Engineering and world renowned in the field of materials science’) and
The Steadman Hawkins, Greenville Hospital System on pre-clinical and clinical trials to further validate
the OsteoZap™ technology.
Poised to receive another tranche of Business Expansion Scheme funding before year end, the team at
EnBIO, led by Philpott, includes Chairman Paddy Caffrey (former VP and Managing Director of Pfizer
Ireland Pharmaceuticals), Founder/Director John O’Donoghue (formerly a principle engineer in
Guidant/Boston Scientific), Founder and Chief Commercial Officer Joe O’Keeffe (previously founder of hi-
tech start-ups Pentus Technologies, SensL, Nanocomms and MV Technologies), and Non Executive Director
Pat Forristal who has held a number of senior leadership positions in the Pharmaceutical, Medical Devices
and Engineering industries, including Stryker.
Commenting on EnBIO’s progress to date John O’Dea, High Potential Start Up Manager at Enterprise
Ireland said: ‘EnBIO’s innovative products are causing considerable interest amongst the medical device
manufacturing industry worldwide and we at Enterprise Ireland are confident that this new technology
has the potential to be truly ground-breaking. The potential for growth is significant as the EnBio coating
technology can also be applied in several other high-value sectors.’
For further information or to arrange an interview please call:
Hopkins Communications Cork
021 4272200; 087 2540804
EnBIO was incorporated in July 2006 to exploit the CoBlast™ concept invented by John O’Donoghue,
EnBIO’s Chief Technology Officer. In the interim a significant intellectual property portfolio has been put
in place and €3.85M has been raised from angel/private investors, the promoters and Enterprise Ireland.
The company has created a market disruptive technology in the medical implant market, through its
CoBlast™ Technology. CoBlast™ revolutionises the process technology that is used to apply coatings to any
metal implant device. Using its proprietary technology, EnBIO can induce drug eluting capabilities on
metallic implants which meets the unmet demand for the majority of medical implant sectors. The
Company plans to focus on four market segments in the medical sector, namely the orthopaedic, dental,
Cardiac Rhythm Management (CRM) and the stent sectors.
EnBIO’s scientific papers have been published in several prestigious journals and members of the EnBIO
team are regularly speaking at international scientific conferences- a validation of the outstanding
possibilities of this new technology.
Before the end of the year EnBIO will sign a contract with the European Space Agency (ESA) to apply black
pigment for space and satellite applications. In addition, ESA has expressed an interest funding additional
contracts for other non medical applications.
The Company has a strong management team in place with extensive experience and a proven track
record in the development, production, sales and marketing of medical devices. The combined
experience spans sector standard bearers such as Boston Scientific, Johnson & Johnson, Stryker
Orthopaedics and Pfizer Pharmaceuticals, amongst others. The Board of Directors comprises the
Paddy Caffrey, Non-Executive Director and Chairman of the Board.
Paddy is a former VP and Managing Director of Pfizer Ireland Pharmaceuticals and has over 30 years
experience in this industry. He is Chairman of the Governing Board of the Cork Institute of Technology and
is a Director of several Cork based companies.
Dan Philpott, Chief Executive Officer/Founder/Director
Dan has a wide ranging experience (15 years) in managing complex, high technology start-ups, having
previously held senior positions with Digital Equipment Corporation, Intel Ireland and Johnson & Johnson.
John O’Donoghue, Chief Technical Officer/Founder/Director.
John is a member of the team who is responsible for recognising the commercial potential of the CoBlast™
invention. He has in-depth experience (15 years) in this industry, most recently as a principle engineer in
Joe O’Keeffe, Chief Commercial Officer/Founder/Director
Joe has considerable experience in high-technology start-ups, having previously served as CEO/Founder of
Pentus Technologies, Chief Commercial Officer/Founder of SensL, COO/Founder of Nanocomms and of MV
Technologies, all Irish hi-tech start-ups.
Pat Forristal, Non Executive Director
Pat has held a number of senior leadership positions in the Pharmaceutical, Medical Devices and
Engineering industries, both in Ireland and internationally. Most recently Pat was Vice President
(International Advanced Operations) with Stryker, where he had responsibility for Product Innovation,
Business & Process Development and Manufacturing.